The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Shares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license ...

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...

Madison Mills goes over some of the top stories on this segment of Market Minute. eToro (ETTO.PVT) is skyrocketing after ...

In a deal that could top out at about $2.2 billion, Septerna Inc. is getting $200 million up front from Novo Nordisk A/S in a collaboration to develop oral treatments for obesity, type 2 diabetes and ...

The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the ...

U.S. health secretary Robert F. Kennedy Jr. said on Wednesday that the "central focus" of the National Institutes of Health ...

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

The U.S. Food and Drug Administration said on Wednesday it has approved the expanded use of Merck's cancer drug to treat two ...

Dow Jones Top Company Headlines at 9 PM ET: UnitedHealth Group Is Under Criminal Investigation for Medicare Fraud | Dick’s ... UnitedHealth Group Is Under Criminal Investigation for Medicare Fraud ...